Tae Woo Park1,2, Richard Saitz3,4, Kerrie P Nelson5, Ziming Xuan3, Jane M Liebschutz4, Karen E Lasser3,4. 1. a Division of General Internal Medicine, Department of Medicine, Alpert Medical School and Rhode Island Hospital , Providence , Rhode Island , USA. 2. b Department of Psychiatry and Human Behavior , Alpert Medical School and Rhode Island Hospital , Providence , Rhode Island , USA. 3. c Department of Community Health Sciences , Boston University School of Public Health , Boston , Massachusetts , USA. 4. d Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center , Boston , Massachusetts , USA. 5. e Department of Biostatistics , Boston University School of Public Health , Boston , Massachusetts , USA.
Abstract
BACKGROUND: Benzodiazepine use has been associated with addiction-related risks, but little is known about its association with aberrant drug-related behaviors in patients receiving opioids for chronic pain. The authors examined the association between receipt of a benzodiazepine prescription and 2 aberrant drug-related behaviors, early opioid refills and illicit drug (cocaine) use in patients receiving opioids for noncancer chronic pain. METHODS: This was a retrospective cohort study of 847 patients with ≥1 visit to either a hospital-based primary care clinic or one of two community health centers between September 1, 2011, and August 31, 2012. All patients received ≥3 opioid prescriptions written at least 21 days apart within 6 months, and ≥1 urine drug screen during the study period. A Cox proportional hazards model estimated the hazard of a second early opioid refill, defined as an opioid prescription written 7-25 days after the previous prescription for the same drug, as a function of time-varying benzodiazepine prescription. A logistic regression model examined the relationship between benzodiazepine prescription and a positive urine test for cocaine. Models were adjusted for demographics and mental/substance use disorder diagnoses. RESULTS: Twenty-three percent (n = 196) of patients received ≥1 benzodiazepine prescription during the study period. Twenty-two percent (n = 183) of patients had ≥2 early opioid refills, and 11% (n = 93) had ≥1 positive urine drug tests for cocaine. Receipt of benzodiazepine prescription was associated with an increased hazard of having a second early opioid refill, adjusted hazard ratio = 1.54 (95% confidence interval [CI]: 1.09-2.18), but not associated with a positive cocaine test, adjusted odds ratio = 1.07 (95% CI: 0.55-2.23). CONCLUSIONS: Among primary care patients receiving chronic opioid therapy, benzodiazepine prescription was associated with early opioid refills but not with cocaine use. Further research should better elucidate the risks and benefits of prescribing benzodiazepines to patients receiving opioids for chronic pain.
BACKGROUND:Benzodiazepine use has been associated with addiction-related risks, but little is known about its association with aberrant drug-related behaviors in patients receiving opioids for chronic pain. The authors examined the association between receipt of a benzodiazepine prescription and 2 aberrant drug-related behaviors, early opioid refills and illicit drug (cocaine) use in patients receiving opioids for noncancer chronic pain. METHODS: This was a retrospective cohort study of 847 patients with ≥1 visit to either a hospital-based primary care clinic or one of two community health centers between September 1, 2011, and August 31, 2012. All patients received ≥3 opioid prescriptions written at least 21 days apart within 6 months, and ≥1 urine drug screen during the study period. A Cox proportional hazards model estimated the hazard of a second early opioid refill, defined as an opioid prescription written 7-25 days after the previous prescription for the same drug, as a function of time-varying benzodiazepine prescription. A logistic regression model examined the relationship between benzodiazepine prescription and a positive urine test for cocaine. Models were adjusted for demographics and mental/substance use disorder diagnoses. RESULTS: Twenty-three percent (n = 196) of patients received ≥1 benzodiazepine prescription during the study period. Twenty-two percent (n = 183) of patients had ≥2 early opioid refills, and 11% (n = 93) had ≥1 positive urine drug tests for cocaine. Receipt of benzodiazepine prescription was associated with an increased hazard of having a second early opioid refill, adjusted hazard ratio = 1.54 (95% confidence interval [CI]: 1.09-2.18), but not associated with a positive cocaine test, adjusted odds ratio = 1.07 (95% CI: 0.55-2.23). CONCLUSIONS: Among primary care patients receiving chronic opioid therapy, benzodiazepine prescription was associated with early opioid refills but not with cocaine use. Further research should better elucidate the risks and benefits of prescribing benzodiazepines to patients receiving opioids for chronic pain.
Authors: Kathleen W Saunders; Michael Von Korff; Cynthia I Campbell; Caleb J Banta-Green; Mark D Sullivan; Joseph O Merrill; Constance Weisner Journal: J Pain Date: 2012-01-29 Impact factor: 5.820
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Kevin W Chen; Christine C Berger; Darlene P Forde; Christopher D'Adamo; Eric Weintraub; Devang Gandhi Journal: BMC Psychiatry Date: 2011-05-19 Impact factor: 3.630
Authors: Stephanie Parent; Seonaid Nolan; Nadia Fairbairn; Monica Ye; Anthony Wu; Julio Montaner; Rolando Barrios; Lianping Ti Journal: Int J Drug Policy Date: 2019-03-18
Authors: Sebastian T Tong; Kathryn M Polak; Michael F Weaver; Gabriela C Villalobos; Wally R Smith; Dace S Svikis Journal: J Am Board Fam Med Date: 2019 Mar-Apr Impact factor: 2.657
Authors: Bobbi Jo H Yarborough; Scott P Stumbo; Ashley Stoneburner; Ning Smith; Steven K Dobscha; Richard A Deyo; Benjamin J Morasco Journal: Pain Med Date: 2019-06-01 Impact factor: 3.750
Authors: Miguel Ángel Hernández-Rodríguez; Ermengol Sempere-Verdú; Caterina Vicens-Caldentey; Francisca González-Rubio; Félix Miguel-García; Vicente Palop-Larrea; Ramón Orueta-Sánchez; Óscar Esteban-Jiménez; Mara Sempere-Manuel; María Pilar Arroyo-Aniés; Buenaventura Fernández-San José; José Ignacio de Juan-Roldán; Ignatios Ioakeim-Skoufa Journal: Int J Environ Res Public Health Date: 2021-04-29 Impact factor: 3.390